Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 20 Animal Health Companies in the World

In this article, we will take a detailed look at the Top 20 Animal Health Companies in the World with insights into the revenue generated in 2022. For a quick overview of the top 5 animal health companies, read our article Top 5 Animal Health Companies in the World.

The animal health industry is in solid shape for continued growth despite global economic downturns in 2020 due to COVID-19. Medium to long-term livestock and companion animal market trends are essential in determining future market behaviors in the related animal health industry.

The global animal health market is expected to grow at a CAGR of 3.36% from 2023 to 2028, reaching US$45.2 billion by 2028. This growth is driven by several factors, including increasing number of pet owners and their desire for high-quality veterinary care, rising awareness of zoonotic diseases, and numerous technological advancements.

According to Bloomberg, the pet economy is expected to grow more than 50% in coming years, driven by spending on sophisticated drugs and treatments and pampering. The pandemic pet boom added 5 million new pets to U.S. households, a 4% increase. This surge in pet ownership is fueling the growth of the animal healthcare industry. Pet owners are increasingly willing to invest in their pets’ health and well-being, leading to demand for more sophisticated drugs and treatments.

A Look into the Animal Healthcare Industry

Zoetis Inc. (NYSE: ZTS), the world’s largest producer of medicine and vaccinations for pets and livestock, reported a solid second quarter of 2023. The company saw a 9% operational revenue growth and 12% operational adjusted net income growth. This was driven by a diverse portfolio across markets and species. Segment growth was more balanced this quarter, with 11% active growth internationally and 7% growth in the U.S. operations. The first half has primarily been as expected, with 6% operational revenue growth. However, Zoetis Inc. (NYSE: ZTS) expects more substantial growth in the year’s second half, especially in its U.S. companion animal business.

Additionally, in livestock, which has grown 8% year-to-date on an operational basis, Zoetis anticipates unfavorable comparisons in the second half due to the timing of price decreases in Jackson in the U.S. last year and resumption of supply of several products after outages in the first half of 2022.

Elanco Animal Health, Inc. (NYSE:ELAN), a $4.5 billion market cap company, posted a loss of $78 million in its most recent financial year. However, analysts expect Elanco Animal Health, Inc. (NYSE:ELAN) to reach the break-even point in 2024 after incurring a final loss in 2023. This is good news for investors, as it suggests that Elanco Animal Health, Inc. (NYSE:ELAN) is on the right track.

Importance of R&D Investments in the Animal Healthcare Industry

Two leaders in the animal health sector, Kathy Turner of IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Rob Kelly of Zoetis Inc. (NYSE:ZTS), believe that companies should continue to invest in R&D during the current economic downturn. They acknowledge that it will be difficult for all firms to maintain the same level of pre-COVID-19 spending, but they argue that R&D is essential to the industry’s long-term success. European animal healthcare companies spend 8% of revenue on R&D, investing over €600 million annually in new product development.

didesign021/Shutterstock.com

Methodology

To rank the top 20 animal health companies in the world, we sourced data from Pharma Shots and Fierce Pharma. We have mentioned annual revenue with each company.

Top 20 Animal Health Companies in the World

  1. Immucell Corp (NASDAQ:ICCC)

Annual Revenue in 2022 (Million USD): 19

ImmuCell Corp (NASDAQ:ICCC), an animal health company, develops, manufactures, and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. However, the company’s earnings have declined by an average of 10.5% per year over the past five years.

  1. Dechra

Annual Revenue in 2022 (Million USD):  827

Swedish investment firm E.Q.T. proposes acquiring Dechra Pharmaceuticals in an all-cash deal worth £4.6 billion ($5 billion). This represents a premium of 51% on Dechra’s closing stock price, making it one of the most significant potential UK take-private deals this year.

  1. Animal Care Group Plc

Annual Revenue in 2022 (Million USD): 86.9 

Animal Care Group Plc, a UK-based international veterinary pharmaceutical company, develops and markets prescription and over-the-counter products that improve animal health and well-being. The company operates in three categories: companion animals, equine and other, and production animals. Its essential product is Daxocox, a differentiated COX-2 inhibitor for treating chronic pain in dogs.

  1. SeQuent

Annual Revenue in 2022 (Million USD): 170

SeQuent has rapidly become India’s leading animal health company, establishing a global niche with its unique business model. The company has grown from acquiring and integrating businesses in key international markets to successfully scaling and consolidating its operations.

  1. KRKA

Annual Revenue in 2022 (Million USD): 1.7

KRKA d.d. shareholders have enjoyed a total shareholder return (TSR) of 30% over the past year, including dividends. This exceeds the company’s five-year average T.S.R. of 21%, suggesting that investor sentiment is positive.

  1. Vibrac

Annual Revenue in 2022 (Million USD): 195.3

Virbac will continue accelerating in 2023 on two key dimensions: R&D and capital expenditures. Virbac plans to boost its R&D investment to around 8.5% of revenues in 2023 and increase its capital expenditure investments to approximately €100 million. This will help the company prepare for the future, accompany its growth, and increase its medium-term productivity.

  1. Heska Corp (NASDAQ:HSKA)

Annual Revenue in 2022 (Million USD): 257 

According to the Q4 2022 Heska Corp (NASDAQ:HSKA) earnings call, the company had a strong Q4 in 2022, with solid execution, significant investment, and preparation for good momentum entering 2023. The company continued to gain market share, significantly improve gross margin, and deliver 15% to 18% growth in crucial subscription metrics. 2022 was an excellent year for Heska (NASDAQ:HSKA), with a solid performance in premium chemistry analyzer placements, up 28% in the fourth quarter year-over-year.

  1. Norbrook

Annual Revenue in 2022 (Million USD): 281

Norbrook, a leading global provider of veterinary pharmaceuticals, enhances the health of farm and companion animals through growth and innovation. The company aims to provide a balanced portfolio of products to its customers and end users, focusing on developing new veterinary products, being the first generic to market where possible, and differentiating its products through features and benefits.

  1. OuroFino

Annual Revenue in 2022 (Million USD): 340.87

Ourofino, a Brazilian veterinary pharmaceutical company, develops, produces, and sells veterinary drugs, vaccines, and other veterinary products for production and companion animals. In 2022, Ourofino’s net revenue exceeded R$ 1 billion, a 15% increase over 2021. EBITDA reached R$ 207.2 million, a 20.1% increase over 2021.

  1. Neogen Corp (NASDAQ:NEOG)

Annual Revenue in 2022 (Million USD): 527

Neogen Corp (NASDAQ:NEOG) experienced higher-than-normal input cost inflation in fiscal 2023, impacting operating results. While pricing actions mitigated some inflationary pressures, ongoing inflation could impact customer purchasing decisions and order patterns in fiscal 2024, albeit at a decreasing rate.

  1. Vetoquinol

Annual Revenue in 2022 (Million USD): 570

In 2022, Vetoquinol reported sales of €540m and net income of €63m from farm and pet animal healthcare products. Vetoquinol adopted its new strategic plan in 2022, setting its direction and roadmap for the next five years.

  1. Eco Animal Health

Annual Revenue in 2022 (Million USD): 82.19

Eco Animal Health Group plc is a UK-based animal health company that develops, registers, and markets pharmaceutical products for global markets. Its patented drug, Aivlosin, is a macrolide antibiotic for treating respiratory and enteric diseases in pigs and poultry. The company also offers generic endectocides and other antiparasitic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic.

  1. Phibro Animal Health Corp (NASDAQ:PAHC)

Annual Revenue in 2022 (Million USD): 942

Phibro Animal Health Corp’s (NASDAQ:PAHC) net sales increased 5% to $244.6 million in Q4 2022, while net income decreased 59% to $7.2 million. Despite the decline in net income, Phibro’s sales growth of more than 20% in 2022 put it in the top tier of animal health companies.

  1. Orion

Annual Revenue in 2022 (Million USD): 1,412 

In 2023, net sales of Orion are expected to be slightly higher than in 2022, excluding EUR 228m ODM-208 upfront payment (2022 net sales without ODM-208 upfront payment: EUR 1,113m).

  1. IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Annual Revenue in 2022 (Million USD): 3,367

IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported strong financial results for Q2 of 2023, with revenue up 10% reported and 10% organic to $1.07 billion.

Click to continue reading and see the Top 5 Animal Health Companies in the World.

Suggested Articles:

Disclosure. None. Top 20 Animal Health Companies in the World is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99 a month.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!